Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease
- PMID: 33722861
- DOI: 10.1136/gutjnl-2021-324214
Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease
Keywords: crohn's disease; inflammatory bowel disease; infliximab.
Conflict of interest statement
Competing interests: RMB is editor in chief of Frontline Gastroenterology and BMJ Open Gastroenterology. JJA is the social media editor of BMJ Open Gastroenterology.
Comment on
-
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.Gut. 2022 Jan;71(1):34-42. doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31. Gut. 2022. PMID: 33384335 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical